JIP
NBIX icon

Jaffetilchin Investment Partners’s Neurocrine Biosciences NBIX Stock Holding History

Jaffetilchin Investment Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-22
Closed -$2.54K – 940
2024
Q3 		$2.54K Buy
+22
New +$3.02K ﹤0.01% 1147

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jaffetilchin Investment Partners's NBIX Position: Q4 2024 in Review

Jaffetilchin Investment Partners sold out of Neurocrine Biosciences (NBIX) in Q4 2024, closing a stake of 22 shares — an estimated $2.54K sold.

Jaffetilchin Investment Partners first reported a position in NBIX in Q3 2024 and held it in 1 quarter. The position peaked at $2.54K in Q3 2024. 601 funds tracked by Wall St. Rank hold NBIX as of Q4 2024.

  • Jaffetilchin Investment Partners reported no remaining Neurocrine Biosciences position as of Q4 2024 after selling out during the quarter.
  • Jaffetilchin Investment Partners sold 22 Neurocrine Biosciences shares in Q4 2024, an estimated $2.54K.
  • Jaffetilchin Investment Partners first reported a position in Neurocrine Biosciences in Q3 2024 and held it in 1 quarter.
  • Jaffetilchin Investment Partners's Neurocrine Biosciences position peaked at $2.54K in Q3 2024.
  • 601 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2024.

Based on Jaffetilchin Investment Partners's 13F filing for Q4 2024, filed 13 Feb 2025.